Loading
The molecular landscape: the targets and how often each appears, the pathways, the mechanics stages and the preclinical models.
The targets of this cancer's medicines and the ones linked to it directly.
| Target / alteration | Prevalence | Measure | Source |
|---|---|---|---|
| CSF1R TGCT only, where the CSF1R-positive macrophage mass is the tumour bulk (West 2006, doi:10.1073/pnas.0507321103) | 100% | CSF1 overexpression by ISH/IHC in tenosynovial giant cell tumour / PVNS (57 of 57); CSF1 translocation in 61% | doi.org |
| GD2 (disialoganglioside) Roth 2014 (Cancer); recurrent samples stained more intensely than primaries | 100% | IHC, GD2 in 44 of 44 osteosarcoma specimens | doi.org |
| CDK4/6 | >90% | Well-/dedifferentiated liposarcoma CDK4 amplification | Wikipedia |
| EZH2 Tazemetostat withdrawn March 2026 | >90% | INI1 (SMARCB1) loss in epithelioid sarcoma (EZH2 dependency) | FDA |
| NTRK <1% in adult common cancers | >90% | Infantile fibrosarcoma (ETV6-NTRK3) | Wikipedia |
| MDM2 | 90% | MDM2 amplification in well/dedifferentiated liposarcoma | doi.org |
| KIT PDGFRA in ~10% | 75-80% | GIST KIT mutation | Wikipedia |
| FAP | 60-90% | Tumour and stromal FAP | Wikipedia |
| MAGE-A4 HLA-A*02 needed for TCR-T; ~40-45% of population | 60-80% | Synovial sarcoma, IHC/RNA | Wikipedia |
| PDGFRB | more than 90% | COL1A1-PDGFB fusion in dermatofibrosarcoma protuberans, the PDGFRB-driven sarcoma imatinib treats | doi.org |
How common each drug target or alteration is in this cancer. Population-level and approximate; see the target page for detail. Full matrix.